Patent ID: 9382512
Filing Date: 2016-07-05
CPC Classification: C12N,G01N,Y10S

Claim Text:
1. An in vitro method of altering fucosylation of a human mesenchymal stem cell surface, wherein sialyl-Lewis x structures are produced to on protein linked O-glycans and N-glycans on said mesenchymal stem cell surface and wherein a sialyl-structure of said sialyl Lewis x structures is α3-linked Neu5Ac (N-acetylneuraminic acid), comprising the steps of: a) culturing mesenchymal stem cells in non-NeuGc (N-glycolylneuraminic acid) and serum free culture medium; b) subculturing said mesenchymal stem cells of step a) at least once in non-NeuGc and serum free culture medium so that said sialyl Lewis x structures on the said mesenchymal stem cell surface protein linked O-glycans consist essentially of only α3-sialylated Lewis x structures, wherein said α3-sialylated Lewis x structures are α3-sialylated N-acetyllactosamines; c) α3-fucosylating said mesenchymal stem cells of step b) with guanosine 5′-diphospho-β-L-fucose (GDP-Fuc) and recombinant α1,3-fucosyltransferase enzyme, wherein α3-fucosylation results in formation of α3-fucosylated sialyl-Lewis x structures on said mesenchymal stem cell surface, wherein said α3-fucosylated sialyl-Lewis x structures are α3-fucosylated N-acetyllactosamines; d) assaying levels of α3-linked Neu5Ac structures, and optionally α6-linked sialic acid structures, on said mesenchymal stem cell surface prior to and/or after step c), wherein said assaying is performed by mass spectrometry or a glycan binding molecule, wherein said glycan binding molecule comprises a protein, an enzyme, a lectin or an antibody that recognizes an α3-sialylated glycan structure; and e) contacting said α3-sialylated and α3-fucosylated sialyl-Lewis x structures on said mesenchymal stem cell surface with selectin for selectin directed targeting of said mesenchymal stem cells.